08:15 AM EDT, 09/25/2024 (MT Newswires) -- Alvotech ( ALVO ) said Wednesday it initiated a confirmatory patient study for AVT16, a biosimilar candidate to Takeda Pharmaceutical's ( TAK ) Entyvio, or vedolizumab.

The study aims to compare the efficacy, safety, and immunogenicity of AVT16 with Entyvio in patients aged 18 to 80 years with moderate to severe ulcerative colitis, Alvotech ( ALVO ) said.

Entyvio is approved for the treatment of adults with moderate to severe ulcerative colitis as well as for moderate to severely active Crohn's disease.